(Q35090438)

6 August 2017

title

Angiotensin II: a new approach for refractory shock management? (English)

1 reference

6 August 2017

Antoine Kimmoun

1

1 reference

6 August 2017

Bruno Levy

series ordinal

2

1 reference

6 August 2017

publication date

18 December 2014

1 reference

6 August 2017

1 reference

6 August 2017

volume

18

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

694

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

1 December 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

Early management of severe sepsis: concepts and controversies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

Vasopressin versus norepinephrine infusion in patients with septic shock.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13054-014-0694-7

Refractory septic shock: efficacy and safety of very high doses of norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13054-014-0694-7

Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13054-014-0694-7

An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13054-014-0694-7

High-dose norepinephrine treatment: determinants of mortality and futility in critically ill patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4330931

Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25645552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S13054-014-0694-7

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference

6 August 2017

1 reference